Why the study?
Risk estimation and statin eligibility in South Asians are not well understood despite the ethnicity being recognized as an ASCVD risk enhancer.
Does the pooled cohort equation accurately predict 10-year ASCVD risk in South Asians without existing ASCVD?
Does the pooled cohort equation accurately predict 10-year ASCVD risk in South Asians without existing ASCVD?
The pooled cohort equation significantly underestimates 10-year ASCVD risk in South Asians, particularly in those classified as low risk, highlighting the need for population-specific risk assessment.
Answers are grounded in this paper and cite their sources.
PCE underestimation may affect prevention decisions in low-risk South Asians; leaves open validation of ethnicity-specific equations.
South Asian ethnicity is associated with increased atherosclerotic cardiovascular disease (ASCVD) risk and has been identified as a "risk enhancer" in the 2018 American College of Cardiology/American Heart Association Guidelines. Risk estimation and statin eligibility in South Asians is not well understood; we studied the accuracy of 10-years ASCVD risk prediction by the pooled cohort equation (PCE), based on statin use, in a South Asian cohort. This is a retrospective cohort study of Kaiser Permanente Northern California South Asian members without existing ASCVD, age range 30-70, and 10-years follow up. ASCVD events were defined as myocardial infarction, ischemic stroke, and cardiovascular death. The cohort was stratified by statin use during the study period: never; at baseline and during follow-up; and only during follow-up. Predicted probability of ASCVD, using the PCE was calculated and compared to observed ASCVD events for low < 5.0%, borderline 5.0 to < 7.5%, intermediate 7.5 to < 20.0%, and high ≥ 20.0% risk groups. A total of 1835 South Asian members were included: 773 never on statin, 374 on statins at baseline and follow-up, and 688 on statins during follow-up only. ASCVD risk was underestimated by the PCE in low-risk groups: entire cohort: 1.8 versus 4.9%, p < 0.0001; on statin at baseline and follow-up: 2.58 versus 8.43%, p < 0.0001; on statin during follow-up only: 2.18 versus 7.77%, p < 0.0001; and never on statin: 1.37 versus 2.09%, p = 0.12. In this South Asian cohort, the PCE underestimated risk in South Asians, regardless of statin use, in the low risk ASCVD risk category.
No takes yet. Share an insight, caveat, or question.
Mantri et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: